Ruby Wu
Columbia University
4 Papers
12 Citations
Ruby Wu is an academic researcher from Columbia University. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 2, co-authored 3 publications.
Chat about Author
Papers
Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer
Tizita Z. Zeleke,Qingfei Pan,Codruta Chiuzan,Maika Onishi,Yuxin Li,Haiyan Tan,Mariano J. Alvarez,Erin Honan,Min Yang,Pei Ling Chia,Partha Mukhopadhyay,S. Kelly,Ruby Wu,Kathleen Fenn,Meghna S. Trivedi,Melissa K. Accordino,Katherine D. Crew,Dawn L. Hershman,Mathew S. Maurer,Simon Jones,Anthony A. High,Junmin Peng,Andrea Califano,Kevin Kalinsky,Jiyang Yu,Jose Silva +25 more
TL;DR: A network-basedHDAC6 score is developed which could predict sensitivity to the leading HDAC6 inhibitor ricolinstat in preclinical models, as well as patients with HR+/HER2− breast cancer that received ricol Instat in a phase 1b clinical trial.
41
Network-based assessment of HDAC6 activity is highly predictive of pre-clinical and clinical responses to the HDAC6 inhibitor ricolinostat
Tizita Z. Zeleke,Qingfei Pan,Cody Chiuzan,Maika Onishi,Mariano J. Alvarez,Erin Honan,Min Yang,Pei Ling Chia,Partha Mukhopadhyay,Sean A. Kelly,Ruby Wu,Kathleen Fenn,Meghna S. Trivedi,Melissa K. Accordino,Katherine D. Crew,Dawn L. Hershman,Matthew Maurer,Simon Jones,Andrea Califano,Kevin Kalinsky,Jiyang Yu,Jose M. Silva +21 more
TL;DR: The results of the first clinical trial evaluating the activity of ricolinostat plus nab-paclitaxel in metastatic BC patients showed that the two agents can be safely combined, that clinical activity is identified specifically in patients with HR+/HER2- disease, and that the HDAC6 score was predictive of response.
Network-Based Assessment of HDAC6 Activity is Highly Predictive of Pre-Clinical and Clinical Responses to the HDAC6 Inhibitor Ricolinostat
Tizita Z. Zeleke,Qingfei Pan,Cody Chiuzan,Maika Onishi,Mariano J. Alvarez,Erin Honan,Min Yang,Pei Ling Chia,Partha Mukhopadhyay,Sean A. Kelly,Ruby Wu,Kathleen Fenn,Meghna S. Trivedi,Melissa K. Accordino,Katherine D. Crew,Dawn L. Hershman,Matthew Maurer,Simon Jones,Andrea Califano,Kevin Kalinsky,Jiyang Yu,Jose M. Silva +21 more
TL;DR: The results of the first clinical trial evaluating the activity of ricolinostat plus nab-paclitaxel in metastatic BC patients showed that the two agents can be safely combined, that clinical activity is identified specifically in patients with HR+/HER2- disease, and that the HDAC6 score was predictive of response.
5
A comparison of nurses' and physicians' perception of cancer treatment burden based on reported adverse events.
TL;DR: Differences in the perception of burden of AEs can lead to different treatment decisions and symptom management strategies, and having provider consistency, training, or a collaborative approach in follow-up care between nurses and physicians is important to ensure continuity in care delivery.